Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Octreotide in Advanced Hepatocellular Carcinoma
NCT00241020Phase 3Completed
- Sponsor
- Novartis
- Start
- Jun 2002
- Primary completion
- Oct 2005
- Modality
- Peptides
01
Overview
Phase 3, randomised, double-blind trial of octreotide in hepatocellular carcinoma (HCC), sponsored by Novartis. Primary endpoint: Overall Survival. Started Jun 2002; status: completed.
02
Drugs
octreotide
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00241020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00241020.